Revance Therapeutics Appoints Steve Kreider as Chief Revenue Officer to Drive Growth.
- Revance Therapeutics appointed Steve Kreider as Chief Revenue Officer to enhance U.S. sales and revenue strategies.
- Kreider brings over 20 years of aesthetic and therapeutic commercial leadership experience to Revance.
- His expertise aims to drive growth and strengthen Revance's market presence in the competitive aesthetics industry.
Revance Therapeutics Strengthens Leadership with New Chief Revenue Officer
Revance Therapeutics, a prominent player in the aesthetics and skincare industry, makes a significant move by appointing Steve Kreider as Executive Vice President and Chief Revenue Officer for Aesthetics and Therapeutics. This newly created role is pivotal as Kreider is tasked with directing U.S. sales and revenue strategies across both sectors. As the company navigates a competitive landscape, Kreider's extensive experience and strategic vision are seen as critical assets to enhance Revance's commercial approach and drive sustainable growth.
Kreider joins Revance with over 20 years of experience in commercial leadership within the aesthetics and therapeutics fields. His previous positions include Senior Vice President at Cutera and various leadership roles at Ortho Dermatologics, Merz Aesthetics, and Medicis. CEO Nadeem Moiz expresses enthusiasm about Kreider's appointment, noting his proven track record in brand transformation and successful product launches. Kreider's expertise is expected to be instrumental in accelerating growth across Revance's diverse portfolio, which includes innovative products like DAXXIFY® (DaxibotulinumtoxinA-lanm), the RHA® Collection of dermal fillers, SkinPen®, and MicroPen EVO™.
Under Kreider's leadership, Revance aims to not only strengthen its market presence but also enhance its commercial execution to unlock long-term potential. The company is deeply committed to addressing the evolving demands of consumers and healthcare providers through continuous innovation in its aesthetics and skincare offerings. With Kreider at the helm of revenue strategies, Revance is well-positioned to capitalize on growth opportunities and maintain its competitive edge in the dynamic aesthetics industry.
In addition to Kreider's appointment, Revance continues to focus on its global reach, with products available in 60 countries. The company's commitment to innovation reinforces its strategy of delivering high-quality solutions that meet the needs of both professionals and patients in the aesthetics and therapeutics markets. As the company moves forward, Kreider's strategic insights will likely play a crucial role in shaping Revance's future initiatives and overall success.
Overall, the appointment of Steve Kreider signifies Revance Therapeutics' dedication to enhancing its commercial leadership and sustaining growth in a competitive environment, reflecting a proactive approach to the challenges and opportunities within the aesthetics sector.
